PREVENT Project Results Presented at AACR

Date Posted: 

Friday, April 13, 2018


The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program designed to support development of the best ideas in cancer prevention using National Cancer Institute contract resources. The program is a pipeline that focuses on unmet needs in prevention that are not adequately addressed by the private sector. NCI actively partners with successful applicants to help them move their novel cancer preventive chemical or biological agents (singly or in combination) and biomarkers from the lab bench towards IND filing, proof-of principle clinical testing and registration or validation.

NCI is participating in the American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2018 at McCormick Place North/South in Chicago, IL, including presenting the following research results from PREVENT-supported projects:

Date: Sunday, April 15
Time: 1:00 PM–5:00 PM
Section 34, Vaccines 1
Exhibit Hall A, McCormick Place South (Level 3)
#717, Mouse model for the development of preventive and therapeutic vaccines against microsatellite-unstable cancers—M Kloor, M Oezcan, A Ahadova, Y Yuan, P Bork, S Sei, R Shoemaker, O Gelincik, S Lipkin, J Gebert, M von Knebel Doeberitz


Date: Monday, April 16
Time: 8:00 AM - 12:00 PM
Section 11, Molecular Mechanisms and Targets for Cancer Prevention
Exhibit Hall A, McCormick Place South (Level 3)
#1250, Evaluation of the prevention by pioglitazone/metformin of ER-positive and ER-negative mammary cancers occurring in rodents on a high-fat diet—BK Dunn, C. Suen, C. Grubbs

#1266, Downregulation of PD-L1 by NSAID administration augments the effects of a multi-antigen vaccine for the prevention of adenomatous polyps in APC(Min/+) mice—M. L. Disis, L. R. Corulli, C. Grubbs, R. A. Lubet, P. Cowan, E. Gad

Time: 5:30 - 6:30 PM
NCI/NIH-Sponsored Session
Rm W192 – McCormick West
The NCI PREVENT Program: Translating Innovative Ideas in Cancer Prevention to the Clinic – Shizuko Sei, Mark Miller, Elizabeth Glaze


Date: Tuesday, April 17
Time: 8:00 AM–12:00 PM
Section 37, Pharmacogenetics and Pharmacogenomics
Exhibit Hall A, McCormick Place South (Level 3)
#3890, Interspecies comparison of in vitro endoxifen metabolism—Muzzio, Z Huang, ER Glaze, DL McCormick

Time: 1:00 PM–5:00 PM
Section 41, Pharmacokinetics and Pharmacodynamics
Exhibit Hall A
McCormick Place South (Level 3)
#4931, Enhanced oral bioavailability of 3,3’-diindolylmethane administered in a self-microemulsifying drug delivery system (SMEDDS)—WD Johnson, M Muzzio, TL Horn, MA Zeligs, ER Glaze, DL McCormick

#4933, Six-month oral toxicity study of endoxifen in rat—TL Horn, WD Johnson, CJ Detrisac, PT Curry, ER Glaze, DL McCormick

Time: 3:00 pm–5:00 pm
Session MS.PR01.01
Preclinical Studies of Cancer Prevention
McCormick Place South (Level 5) - Room S505
#4989, Efficacy of erlotinib and/or naproxen when administered by intermittent dosing schedules in the prevention of chemically induced urinary bladder cancers—A Mohammed, MS Miller, RA Lubet, C Suen, S Sei, RH Shoemaker, CJ Grubbs

#4983, Intermittent dosing regimens of naproxen and aspirin inhibit azoxymethane-induced rat colon adenoma progression to adenocarcinoma and carcinoma invasion—A Mohammed, NB Janakiram, V Madka, Y Zhang, A Singh, L Biddick, Q Li, S Lightfoot, VE Steele, R Lubet, MS Miller, CS Suen, S Sei, CV Rao